RT Journal Article
SR Electronic
T1 Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.17.23298635
DO 10.1101/2023.11.17.23298635
A1 Fusaroli, Michele
A1 Polizzi, Stefano
A1 Menestrina, Luca
A1 Giunchi, Valentina
A1 Pellegrini, Luca
A1 Raschi, Emanuel
A1 Weintraub, Daniel
A1 Recanatini, Maurizio
A1 Castellani, Gastone
A1 De Ponti, Fabrizio
A1 Poluzzi, Elisabetta
YR 2024
UL http://medrxiv.org/content/early/2024/04/10/2023.11.17.23298635.abstract
AB Introduction Impulsivity induced by dopaminergic agents, like pramipexole and aripiprazole, can lead to behavioral addictions impacting social functioning and quality of life of patients and families (e.g., resulting in unemployment, marital problems, anxiety). These secondary effects, interconnected in networks of signs and symptoms, are usually overlooked by clinical trials, not reported in package inserts, and neglected in clinical practice.Objective This study explores the syndromic burden of impulsivity induced by pramipexole and aripiprazole, pinpointing key symptoms for targeted mitigation.Methods An event-event Information Component (IC) on the FDA Adverse Event Reporting System (January 2004 – March 2022) identified the syndrome of events disproportionally co-reported with impulsivity, separately for pramipexole and aripiprazole. A greedy-modularity clustering on composite network analyses (PPMI, Ising, Φ) identified subsyndromes. Bayesian network modeling highlighted possible precipitating events.Results Suspected drug-induced impulsivity was documented in 7.49% pramipexole and 4.50% aripiprazole recipients. The highest IC concerned obsessive-compulsive disorder (reporting rate = 26.77%; IC median = 3.47, 95%CI = 3.33-3.57) and emotional distress (21.35%; 3.42, 3.26-3.54) for pramipexole, bankruptcy (10.58%; 4.43, 4.26-4.55) and divorce (7.59%; 4.38, 4.19-4.53) for aripiprazole. The network analysis identified delusional jealousy and dopamine dysregulation subsyndromes for pramipexole, obesity-hypoventilation and social issues for aripiprazole. The Bayesian network highlighted anxiety and economic problems as potentially precipitating events.Conclusion The under-explored consequences of drug-induced impulsivity significantly burden patients and families. Network analyses, exploring syndromic reactions and potential precipitating events, complement traditional techniques and clinical judgment. Characterizing the secondary impact of reactions will support informed patient-centered decision-making.HighlightsDrug-induced impulsivity significantly impacts patients’ lives. Network analyses help characterize reactions as syndromes.We explore the impulsivity syndrome and subsyndromes resulting from pramipexole and aripiprazole.The manifestation of drug-induced impulsivity was different for the two drugs. Anxiety and economic problems bridge between other symptoms and could be important therapeutical targets.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used only openly available human data that were originally located at: https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.htmlI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data we used comes from the FDA Adverse Event Reporting System (FAERS), and is made publicly available by the FDA as quarterly data downloadable at https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html. The algorithm for cleaning FAERS data is open-source at https://github.com/fusarolimichele/DiAna, and the cleaned database is available on an OSF repository and through the R package DiAna. https://osf.io/k9v6s/